Apoptosis

Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance

Friday, October 22, 2021 - 11:00am

REHOVOT, Israel, Oct. 22, 2021 (GLOBE NEWSWIRE) --  Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced a publication in Nature Cancer that provides new insight into the underlying mechanism of the therapeutic resistance of cancer cells and the significant role of insulin receptor substrate 1 (IRS1) pathway on epithelial growth factor receptor (EFGR) inhibition therapy. NT219, currently being evaluated in a Phase 1/2 clinical trial, is a novel small molecule inhibiting simultaneously IRS1/2 and STAT3.

Key Points: 
  • NT219, currently being evaluated in a Phase 1/2 clinical trial, is a novel small molecule inhibiting simultaneously IRS1/2 and STAT3.
  • The lead author of the publication is Ravid Straussman, M.D., Ph.D., Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • The article demonstrated mechanistic evidence of cancer cells' inherited therapeutic resistance, termed chance to persist (CTP).
  • Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies by overcoming tumor immune evasion and drug resistance.

Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore

Friday, October 22, 2021 - 2:00am

SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and oncology portfolios, tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®).

Key Points: 
  • "Both pemigatinib and tafasitamab address strong unmet needs in rare patient populations.
  • Our teams look forward to working closely with Incyte to ensure all eligible patients have access to these therapies at the earliest opportunity."
  • "We look forward to a successful and mutually beneficial partnership, working together with a shared goal of improving patient outcomes."
  • In January 2020, MorphoSys and Incyte entered into a Collaboration and License agreement to further develop and commercialize tafasitamab globally.

Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection

Thursday, October 21, 2021 - 3:18pm

New York, NY, and Tel Aviv, ISRAEL, Oct. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the publication of an article entitled “A Practical Approach to SARS-CoV-2 Testing in Pre and Post Vaccination Era” in the peer-reviewed Journal of Clinical Virology, available online at https://www.sciencedirect.com/science/article/pii/S2667038021000363?via%... , that highlights the clinical utility of combining the cPass neutralizing antibody test in the vaccinated and COVID-recovered populations with  PCR testing  in the unvaccinated and not previously infected to reduce COVID-19 transmission. Todos Medical is hosting a webinar entitled “New Paradigm for Measuring Immunity in Pre- and Post-Vaccination Era” on Friday, October 22nd, 2021 at 12:00pm ET for The Society for Post-Acute and Long-Term Care Medicine (“AMDA”), and is available for anyone to attend virtually on Todos’ YouTube Channel at: https://www.youtube.com/channel/UCWsJLl1iB9qlZUSicQ9e-Mg.

Key Points: 
  • This could include a combination of qPCR (for non-vaccinated and susceptible people) and nAb (for previously infected and vaccinated people) assays.
  • cPass sVNT could be a useful tool for substantiating individual immunity in a SARS-CoV-2 post-vaccination era.
  • Provista Dx offers high-throughput SARS-CoV-2 PCR testing and high-throughput semi-quantitative cPass neutralizing antibody testing as services.
  • For more information on Provistas testing services, please contact James Doherty, Sr. Director of Business Development at Provista Diagnostics atdohertyj@provistadx.com.

BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lu

Wednesday, October 20, 2021 - 12:00pm

The positive PDX preclinical data increases our confidence in pursuing SCLC as an indication for plinabulin, which has shown high response rate data in human studies.

Key Points: 
  • The positive PDX preclinical data increases our confidence in pursuing SCLC as an indication for plinabulin, which has shown high response rate data in human studies.
  • The preclinical data presented here supports our intended strategy for developing an option for cancer patients by combining plinabulin and checkpoint inhibitors in SCLC.
  • Plinabulins anti-cancer effect is supported by the positive Phase 3 DUBLIN-3 non-small cell lung cancer study with evidence of the extension of overall survival.
  • Plinabulin, BeyondSprings lead asset, is a selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021

Tuesday, October 19, 2021 - 11:29am

Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.

Key Points: 
  • Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.
    Copenhagen, Denmark; October 19, 2021 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S.), as reported by Johnson & Johnson were USD 1,580 million in the third quarter of 2021.
  • Net trade sales were USD 841 million in the U.S. and USD 739 million in the rest of the world.
  • Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC formulations, under the exclusive worldwide license to Janssen Biotech, Inc. (Janssen) to develop, manufacture and commercialize daratumumab.
  • Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab.

Global Peritoneal Cancer Pipeline Research Report 2021: Focus on 50+ Companies and 50+ Pipeline Drugs - ResearchAndMarkets.com

Monday, October 18, 2021 - 3:58pm

"Peritoneal cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 50+ companies and 50+ pipeline drugs in Peritoneal cancer pipeline landscape.

Key Points: 
  • "Peritoneal cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 50+ companies and 50+ pipeline drugs in Peritoneal cancer pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal cancer R&D.
  • This segment of the Peritoneal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The drug is being investigated in Phase II stage of development for the treatment of peritoneal cancer, HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, and Fallopian Tube Cancer.

Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

Monday, October 18, 2021 - 12:30pm

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).
  • Completing patient enrollment in IMerge Phase 3 brings us one step closer to delivering imetelstat as a potential treatment alternative for patients with lower risk MDS who are relapsed or refractory to ESAs.
  • IMerge Phase 3 is a double-blind, randomized, placebo-controlled Phase 3 clinical trial with registrational intent.
  • The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3

Monday, October 18, 2021 - 6:00am

Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accents pre-clinical stage METTL3 program.

Key Points: 
  • Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accents pre-clinical stage METTL3 program.
  • Christelle Huguet, Senior Vice President, Head of Research, External Innovation and Early Development, Ipsen, said Oncology is a key focus area for Ipsen as we grow our pipeline.
  • We are delighted to partner with Accent to progress the METTL3 program as we continue our expansion into hematologic oncology.
  • Accent Therapeutics novel investigational small molecule inhibitors of METTL3 seek to treat specific sub-types of AML with high unmet medical need.

"Pre-IPO" Biotech Startup Kills Advanced Stage Breast Cancers; Accepts Global Crowdfunding Investors

Thursday, October 14, 2021 - 1:37pm

SAN FRANCISCO, Oct. 14, 2021 /PRNewswire/ --In recognition of Breast Cancer Awareness Month, DeoBioSciences, Inc. ("DBS"), a minority/female founded, preclinical stage, biotech company, is highlighting its impressive research results against several types of treatment-resistant breast cancer.

Key Points: 
  • SAN FRANCISCO, Oct. 14, 2021 /PRNewswire/ --In recognition of Breast Cancer Awareness Month, DeoBioSciences, Inc. ("DBS"), a minority/female founded, preclinical stage, biotech company, is highlighting its impressive research results against several types of treatment-resistant breast cancer.
  • DeoBioSciences' drug candidate, DBX-31, can selectively target and kill a wide range of tough, treatment-resistant, advanced stage, metastatic cancer types, including both HER2+ breast cancer and two types of the notorious triple negative breast cancer.
  • DeoBioSciences is a privately held, pre-clinical stage, biotech developer with a principal office in suburban Atlanta, Georgia.
  • DBS is currently developing DBX-31, a naturally sourced anticancer protein to address a wide range of advanced stage cancer types through external apoptotic induction.

InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board

Tuesday, October 12, 2021 - 10:00am

InteRNA Technologies , a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today the appointment of Andrea van Elsas, PhD, as a new member of the Companys Supervisory Board.

Key Points: 
  • InteRNA Technologies , a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today the appointment of Andrea van Elsas, PhD, as a new member of the Companys Supervisory Board.
  • Dr. van Elsas transitions from the Companys Scientific Advisory Board where he served as a member since February 2019.
  • He will succeed Mark Vaeck, PhD, who has stepped down from his position on the Supervisory Board.
  • Over the past two years, it has been great to see how Roel and his team advanced the first lead candidate, INT-1B3, from preclinical proof-of-concept to its clinical evaluation, added Dr. Andrea van Elsas, member of InteRNAs Supervisory Board.